Following adults with obstructive sleep apnea over time in Hong Kong
Follows adults with obstructive sleep apnea to study heart disease risk and thinking decline.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Prospective Study on Patients With Obstructive Sleep Apnea in Hong Kong (PrOSA)
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 30 Aug 2020
- Expected to end
- 29 Aug 2028
- Type of study
- Observational
- Record updated
- 20 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who may have obstructive sleep apnea, where the airway keeps closing during sleep. It follows them over time to study heart risk and memory and thinking decline.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Suspected obstructive sleep apnea syndrome, not yet treated.
- Earlier treatment
- People whose sleep apnea has already been treated cannot join.
Main reasons for not taking part
- Sleep apnea already treated
- Short expected lifespan due to an illness not related to sleep apnea
- HIV, advanced kidney disease or uncontrolled cancer
- Alcohol or drug abuse on record within 1 year before joining
- Not able to speak, read and understand Chinese or English, or to answer questions and follow instructions
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- suspected obstructive sleep apnea syndrome
- aged 18 or above
- must be able to speak, read and understand Chinese or English
- possess the ability to respond to questions and follow instructions
Who cannot take part
- documented alcohol or drug abuse up to 1 year prior to inclusion in the study
- a limited life expectancy due to illness unrelated to sleep apnea
- human immunodeficiency virus (HIV),
- advanced renal disease,
- uncontrolled malignancies
- already treated sleep apnea,
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Obstructive sleep apnea syndrome (OSAS) is a common disorder with prevalence rates of at least 4% among the middle-aged male Caucasians and Hong Kong (HK) Chinese populations. It is characterized by repetitive episodes of upper airway obstruction, causing intermittent hypoxia, sleep fragmentation, disabling daytime sleepiness, impaired cognitive function and poor health status. OSAS patients are at increased risks of non-fatal and fatal cardiovascular morbidity and mortality including sudden death, in addition to being more prone to road traffic accidents. However, there is no long term follow up of patients with OSAS on the incidence of cardiovascular disease, compliance on the therapy and the impact of the quality of life. The study is aimed to carry out a prospective observational study assessing the role of OSAS as a possible cause of increased cardiovascular risk and cognitive decline.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective Study on Patients With Obstructive Sleep Apnea in Hong Kong (PrOSA)
- Plain-language title
- Following adults with obstructive sleep apnea over time in Hong KongGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 February 2024